Exploratory analyses from Phase 3 INDIGO study show lower seizure rates in patients treated with vorasidenib vs. placebo

Category Primary study
Conference11th Congress of the European Academy of Neurology
Year 2025
This article has no abstract
Epistemonikos ID: 213f721d70699fae596081538b68a07cf35f61ac
First added on: Mar 28, 2026